SB 239063, , >98% (HPLC)

SB 239063, , >98% (HPLC)

Application

SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 mitogen activated protein kinase (MAPK) on the viability and apoptosis of cardiomyocytes under glutathione S-transferase (GST) inhibition. It has also been used in neuron-microglia conditioned media (CM) experiments and pharmacokinetics.

Biochem/physiol Actions

Potent p38 MAP kinase inhibitor. Selective for α and β. No activity against γ and δ isoforms.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

SB 239063 helps to decrease neutrophilia, inflammatory cytokines, matrix metallopeptidase 9 (MMP-9) and fibrosis in the lung.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level mp InChI key InChI Manufacturer Form Assay Price Quantity
3573886 SB 239063, , >98% (HPLC) white 100 206-207.2 °C ZQUSFAUAYSEREK-WKILWMFISA-N 1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3/t15-,16- SIGMA-ALDRICH powder >98% (HPLC)
£682.50 (exc VAT) per 25MG
-
+
3573887 SB 239063, , >98% (HPLC) white 100 206-207.2 °C ZQUSFAUAYSEREK-WKILWMFISA-N 1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3/t15-,16- SIGMA-ALDRICH powder >98% (HPLC)
£238.18 (exc VAT) per 5MG
-
+